SCHEMBL10275201

SCHEMBL10275201

Cc1ccc(C=CC(=O)c2ccc3cccc(O)c3n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.55
KMT2A Q03164 5/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 1/20 0.51
CYP3A4 P08684 1/20 0.51
HPGD P15428 1/20 0.51
PIM1 P11309 1/20 0.51
MEN1 O00255 4/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
POLB P06746 2/20 0.48
NPC1 O15118 2/20 0.48
SLC5A1 P13866 1/20 0.48
SLC5A2 P31639 1/20 0.48
CD74 P04233 1/20 0.47
MIF P14174 1/20 0.47
MAOA P21397 3/20 0.47
MAOB P27338 3/20 0.47
METAP2 P50579 1/20 0.45
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28075449 0.88 KMT2A (0.60) MAPTKMT2AKDM4ECYP3A4PIM1
SCHEMBL28075448 0.88 KMT2A (0.60) MAPTKMT2AKDM4ECYP3A4PIM1
SCHEMBL6283674 0.86 KMT2A (0.59) MAPTKMT2AKDM4ECYP3A4PIM1
SCHEMBL28095215 0.86 KMT2A (0.59) MAPTKMT2AKDM4ECYP3A4PIM1
SCHEMBL437765 0.86 KMT2A (0.59) MAPTKMT2AKDM4ECYP3A4PIM1
SCHEMBL10275159 0.85 KMT2A (0.54) MAPTKMT2AKDM4EALDH1A1CYP3A4
SCHEMBL10275506 0.80 MAPT (0.59) MAPTKMT2AKDM4EALDH1A1CYP3A4
SCHEMBL10275586 0.80 USP2 (0.60) MAPTKMT2AKDM4EALDH1A1CYP3A4
SCHEMBL10275204 0.76 PFKFB3 (0.62) MAPTKMT2AKDM4EMEN1RAB9A
SCHEMBL10276338 0.76 PFKFB3 (0.62) MAPTKMT2AKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557823-B2 Family of PFKFB3 inhibitors with anti-neoplastic activities ADVANCED CANCER THERAPEUTICS, LLC (US) 2013-10-15 US claimed
US-20230312728-A1 Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-05 US disclosed
WO-2017208174-A2 METHODS OF TREATING DISEASE WITH PFKFB3 INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-07 WO disclosed
US-8557823-B2 Family of PFKFB3 inhibitors with anti-neoplastic activities ADVANCED CANCER THERAPEUTICS, LLC (US) 2013-10-15 US disclosed
US-20120177749-A1 FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120177749-A1 FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES PFKFB3, PFKFB2, PFKFB1 MAPT 3600/4885KMT2A 2305/4885KDM4E 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.